LYC 55716

Drug Profile

LYC 55716

Alternative Names: LYC-55716

Latest Information Update: 30 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Lycera
  • Class Antineoplastics
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 01 Dec 2016 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Inoperable/Unresectable) in USA (PO) (NCT02929862)
  • 07 Oct 2016 Lycera plans a phase I/IIa trial for Solid tumours (Second-line therapy or greater, Inoperable/Unresectable) in USA (PO) (NCT02929862)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top